What is the equity of Inhibitor Therapeutics this year?
Inhibitor Therapeutics has equity of 5.28 M USD this year.
In 2024, Inhibitor Therapeutics's equity was 5.28 M USD, a -36.34% increase from the 8.3 M USD equity in the previous year.
Inhibitor Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Inhibitor Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating Inhibitor Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Inhibitor Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in Inhibitor Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Inhibitor Therapeutics has equity of 5.28 M USD this year.
The equity of Inhibitor Therapeutics has increased/decreased by -36.34% decreased compared to the previous year.
A high equity is advantageous for investors of Inhibitor Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of Inhibitor Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of Inhibitor Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of Inhibitor Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of Inhibitor Therapeutics include profits, dividend payments, capital increases, and acquisitions.
The equity of Inhibitor Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, Inhibitor Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, Inhibitor Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibitor Therapeutics is expected to pay a dividend of 0 USD.
The current dividend yield of Inhibitor Therapeutics is .
Inhibitor Therapeutics pays a quarterly dividend. This is distributed in the months of .
Inhibitor Therapeutics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Inhibitor Therapeutics is assigned to the 'Health' sector.
To receive the latest dividend of Inhibitor Therapeutics from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.
The last dividend was paid out on 11/1/2024.
In the year 2023, Inhibitor Therapeutics distributed 0 USD as dividends.
The dividends of Inhibitor Therapeutics are distributed in USD.
Our stock analysis for Inhibitor Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibitor Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.